首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   224篇
  完全免费   256篇
  2022年   62篇
  2021年   74篇
  2020年   48篇
  2019年   39篇
  2018年   31篇
  2017年   14篇
  2016年   22篇
  2015年   17篇
  2014年   19篇
  2013年   28篇
  2012年   25篇
  2011年   14篇
  2010年   8篇
  2009年   5篇
  2008年   11篇
  2007年   11篇
  2006年   6篇
  2005年   5篇
  2004年   8篇
  2003年   3篇
  2002年   10篇
  2001年   9篇
  2000年   3篇
  1999年   1篇
  1998年   1篇
  1997年   2篇
  1995年   1篇
  1993年   1篇
  1989年   1篇
  1986年   1篇
排序方式: 共有480条查询结果,搜索用时 250 毫秒
1.
Artichoke leaf extract reduces mild dyspepsia in an open study   总被引:5,自引:0,他引:5  
A recent post-marketing study indicated that high doses of standardised artichoke leaf extract (ALE) may reduce symptoms of dyspepsia. To substantial these findings, this study investigated the efficacy of a low-dose ALE on amelioration of dyspeptic symptoms and improvement of quality of life. The study was an open, dose-ranging postal study. Healthy patients with self-reported dyspepsia were recruited through the media. The Nepean Dyspepsia Index and the State-Trait Anxiety Inventory were completed at baseline and after 2 months of treatment with ALE, which was randomly allocated to volunteers as 320 or 640 mg daily. Of the 516 participants, 454 completed the study. In both dosage groups, compared with baseline, there was a significant reduction of all dyspeptic symptoms, with an average reduction of 40% in global dyspepsia score. However, there were no differences in the primary outcome measures between the two groups, although relief of state anxiety, a secondary outcome, was greater with the higher dosage (P = 0.03). Health-related quality of life was significantly improved in both groups compared with baseline. We conclude that ALE shows promise to ameliorate upper gastro-intestinal symptoms and improve quality of life in otherwise healthy subjects suffering from dyspepsia.  相似文献
2.
3.
Quality of life and chronotherapy   总被引:3,自引:0,他引:3  
The importance of evaluating patient's quality of life (QoL) in clinical practice and research is recognized clearly in oncology. In the advanced phase of disease such an evaluation represents an endpoint as important as survival. Quality of life is both a subjective and multidimensional concept evaluated mainly by validated questionnaires. In colorectal trials involving advanced stage disease the effects of different chemotherapy treatments on QoL were evaluated. Almost all the studies found no deterioration in QoL during chemotherapy. The European Organization for the Research and Treatment of Cancer (EORTC) Chronotherapy Study Group utilized three different approaches to assess QoL. The first centered on the stability of QoL during a 6mon treatment period in patients undergoing chronotherapy. The second centered on research of the biological and clinical determinants of QoL involving features of the circadian activity rhythm and patient survival and the relationship between QoL and patient performance status, response to therapy, and psychosocial variables as well as drug-induced toxicity. The third centered on the clinical effectiveness of psychological intervention on patients undergoing chronotherapy to improve psychosocial status during treatment. This papers reviews the results of EORTC Chronotherapy Group studies on QoL.  相似文献
4.
Quality-adjusted survival estimation with periodic observations   总被引:3,自引:0,他引:3  
Chen PL  Sen PK 《Biometrics》2001,57(3):868-874
Quality-adjusted survival is a measure that integrates both longevity and quality-of-life information. The analysis of quality-adjusted survival in a clinical study with data collected at periodic intervals encounters difficulties due to incomplete information. Based on observed time points, the time axis is partitioned into a set of disjoint time intervals, and under a Markovian assumption on patient's health status, the expected quality-adjusted survival is estimated as the summed product of the quality of life and its mean sojourn time of each health state within partitioned intervals. It is shown that the estimator is asymptotically normal with a simple variance calculation. A simulation study is conducted to investigate the behavior of the estimator, and a stroke study illustrates the use of the estimator.  相似文献
5.
We devised an innovative type of immunocell therapy called BRM (biological response modifier)-activated killer (BAK) therapy, which utilizes most of non-MHC (major histocompatibility complex) restricted lymphocytes, CD56+ cells including T cells and NK cells. Peripheral blood lymphocytes were selected by immobilizing them with anti-CD3 monoclonal antibody, cultured for 2 weeks with serum-free medium containing IL-2, and then were reactivated by 1,000 U/ml of IFN- for 15 min. The patients were infused with about 6×109 BAK cells by intravenous drip infusion at 1-month intervals. All advanced solid cancer patients who had received chemotherapy but for whom it was not effective or have refused chemotherapy were included in the present study. A good marker of impairment of host immune response by chemotherapy is an immunosuppressive acidic protein (IAP) level in serum above 580 g/ml; survival rates were compared with the high (>580 g/ml) and the low (580 g/ml) serum IAP groups. We enrolled in this study 23 immunosuppressed patients whose IAP levels in serum were over 580 g/ml, and 42 immunoreactive solid cancer outpatients whose IAP level in serum were under 580 g/ml and whose performance statuses were over 80% on the Karnofsky scale. After giving informed consent, patients were treated with BAK therapy on an outpatient basis at our hospital. The ethical review board of the Miyagi Cancer Center approved this pilot study. Treated with BAK therapy, the mean survival of immunosuppressed patients was 4.6 months. On the other hand, survival for one of immunoreactive advanced postoperative patients (stage IV) and inoperable lung cancer patients (stage IIIb) was 24.7 months. The difference in survival between the 2 groups was significant (P<0.01). This shows that BAK therapy is not indicated for an advanced cancer patient whose serum IAP is over 580 g/ml, perhaps due to extensive chemotherapy. Overall response to BAK therapy was complete response (CR) in 5 cases, partial response (PR) in 1 case, and prolonged no change (NC) in 26 cases, with an effectiveness rate at 76.2% in 42 advanced stage IIIb and IV cancer patients. BAK therapy has a life-prolonging effect without any adverse effects and maintains satisfactory quality of life (QOL) for advanced cancer patients.  相似文献
6.
Murray S  Cole B 《Biometrics》2000,56(1):173-182
The Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) statistic previously introduced by Glasziou, Simes and Gelber (1990, Statistics in Medicine 9, 1259-1276) combines toxicity, disease-free survival, and overall survival information in assessing the impact of treatments on the lives of patients. This methodology has received positive reviews from clinicians as intuitive and useful, but to date, the variance of this statistic has remained unspecified. We review aspects of the Q-TWiST method for analyzing clinical trial data, extend the method to accommodate multiple treatment arms, and provide closed-form asymptotic variance formulas. We also provide a framework for designing Q-TWiST clinical trials with sample sizes determined using the derived asymptotic variance formulas. Trials currently collecting quality of life data did not have the benefit of these sample size calculation techniques in designing their studies.  相似文献
7.
We present a population model to examine the forces that determined the quality and quantity of human life in early agricultural societies where cultivable area is limited. The model is driven by the non-linear and interdependent relationships between the age distribution of a population, its behavior and technology, and the nature of its environment. The common currency in the model is the production of food, on which age-specific rates of birth and death depend. There is a single non-trivial equilibrium population at which productivity balances caloric needs. One of the most powerful controls on equilibrium hunger level is fertility control. Gains against hunger are accompanied by decreases in population size. Increasing worker productivity does increase equilibrium population size but does not improve welfare at equilibrium. As a case study we apply the model to the population of a Polynesian valley before European contact.  相似文献
8.
9.
目的:探讨透析充分性、微炎症、营养状态对血液透析患者生存质量及长期生存率的影响。方法:随机选择我院血液透析中 心维持透析每周3 次,治疗6 月以上的患者89 例,观察并评估其入组时、入组后第3、6、12、18、24 月的生存质量(KDTA、SF-36)、 营养状况(MQSGA、MAMC)、微炎症(hCRP、IL-6)及透析充分性(iPTH、Kt/V、beta2-MG),并分析透析充分性、营养状况、微炎症与生 存质量、生存率的相关性。结果:89 例患者有9 例死亡,死亡率为10.1 %;iPHT、MQSGA与KDTA、SF-36 呈负相关(P<0.05),Kt/V 与KDTA、SF-36 呈正相关(P<0.05),beta2-MG、胆固醇与KDTA、SF-36 无明显相关(P>0.05);hCRP、IL-6 分别与KDTA、SF-36 呈负相 关(P<0.05);HGS 与KDTA 呈正相关(P<0.05),与SF-36 无明显相关(P>0.05),ALB、MAMC 与KDTA、SF-36 呈正相关(P<0.05); Kt/V、MQSGA、IL-6、iPTH 均与KDAT 及SF-36 存回归关系(P<0.05);Cox 回归模型发现Kt/V、ALB 及开始透析年龄是导致血透 患者死亡的危险因素(P<0.05)。结论:透析充分性、微炎症及营养状况均影响透析患者的生存质量及长期生存率;iPTH 、Kt/V、 MQSGA、IL-6 是其生存质量的独立影响因素,Kt/V、ALB 及开始透析年龄是血透患者的死亡独立危险因素。  相似文献
10.
目的:观察金龙胶囊联合化疗与单纯化疗对晚期肺小细胞癌患者的疗效、生活质量等因素的影响。方法:将99例患有晚期非小细胞肺癌患者随机分为两组:治疗组,在NP化疗方案基础上加服金龙胶囊治疗;对照组,单纯接受NP方案化疗。对99例患者追踪2个月,观察并比较患者的疗效、体质量、生活质量、毒副反应等方面的差异。结果:在NP化疗方案基础上加服金龙胶囊治疗在患者疗效评价方面与单纯NP方案化疗相比不具有统计学差异(P>0.05);在提高患者体质量、改善患者临床症状和生活质量等方面均优于单纯NP方案化疗(P<0.05);在化疗所引发的白细胞、血红蛋白和血小板降低等部分毒副反应发生率方面低于单纯NP方案化疗组(P<0.05)。结论:金龙胶囊联合NP化疗治疗晚期非小细胞肺癌不仅可以起到化疗增效的作用,而且能够明显提高患者生活质量,有效的改善临床症候,降低化疗引发的毒副反应,这一联合治疗方案可以在临床治疗中广泛推广。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号